Investor Notice: Investigation on Behalf of MRNS Shareholders by Faruqi & Faruqi, LLP

Investors of Marinus Pharmaceuticals, Inc. MRNS who have incurred significant losses may have recourse to pursue legal action. The law firm Faruqi & Faruqi, LLP is conducting an investigation into potential legal claims on behalf of Marinus stock and options investors. The investigation pertains to those who have been financially affected during the period from March 17, 2021, to May 7, 2024. Marinus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in developing treatments for rare seizure disorders, with its headquarters based in Radnor, Pennsylvania.

Legal Investigation for MRNS Investors

With a particular focus on investors who have suffered losses exceeding $50,000 in Marinus stock or options, Faruqi & Faruqi, LLP is issuing an alert. The law firm encourages affected individuals to engage in a conversation regarding their legal rights. Senior partner Josh Wilson at Faruqi & Faruqi is available for direct communication. Investors are invited to call him at 877-247-4292 or 212-983-9330 (Ext. 1310) for a confidential discussion pertaining to these matters.

Seeking Recourse for Significant Losses

If you fall into the category of investors who have experienced substantial financial detriment as a result of participating in Marinus stock MRNS or options during the specified timeframe, you may be entitled to legal remedies. Faruqi & Faruqi, LLP aims to assist investors in understanding their rights and exploring potential avenues for recovering their investments. The firm emphasizes the importance of acting swiftly to ensure the best possible outcome for affected shareholders.

investigation, legal, losses